Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

GlaxoSmithKline plc : GSK completes divestment of Lucozade and Ribena to Suntory

01/01/2014 | 07:06am US/Eastern

Issued: Tuesday 31 December 2013, London UK

GlaxoSmithKline (GSK) today completed the previously announced divestment of its nutritional drinks brands Lucozade and Ribena to Suntory Beverage & Food Ltd for £1.35 billion.

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit

About Suntory Beverage & Food Ltd

Suntory Beverage & Food Ltd (SBF) is a leading global soft drink company, headquartered in Japan and listed on the Tokyo Stock Exchange, with an integrated platform across four key regions: Japan, Europe, Oceania and Southeast Asia. SBF has an extensive product line-up and in 2012 was the number 4 supplier of soft drinks globally and 2nd in Japan. SBF's vision is to be the leading global soft drink company recognized for its premium and unique brands.

SBF is a core company of Suntory Group, which was founded in 1899.  With global consolidated sales of over £12 billion in 2012, Suntory has a range of businesses encompassing alcoholic beverages, wellness, food, restaurants and flowers with approximately 200 companies and 29,000 employees across Japan, Europe, Asia Pacific and the Americas. For further information please visit

GSK enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502


Simon Steel

+44 (0) 20 8047 5502


David Daley

+44 (0) 20 8047 5502


Catherine Hartley

+44 (0) 20 8047 5502


US Media enquiries:

Stephen Rea

+1 215 751 4394


Melinda Stubbee

+1 919 483 2510

(North Carolina)

Mary Anne Rhyne

+1 919 483 0492

(North Carolina)

Sarah Alspach

+1 202 715 1048

(Washington, DC)

Jennifer Armstrong

+1 215 751 5664


Analyst/Investor enquiries:

Sally Jackson

+44 (0) 20 8047 5543


Kirsty Collins (SRI & CG)

+44 (0) 20 8047 5534


Tom Curry

+ 1 215 751 5419


Gary Davies

+44 (0) 20 8047 5503


James Dodwell

+44 (0) 20 8047 2406


Jeff McLaughlin

+1 215 751 7002


Ziba Shamsi

+44 (0) 20 8047 3289


Lucy Singah

+44 (0) 20 8047 2248


Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012.

distributed by
Recommend :
React to this article
1h ago GLAXOSMITHKLINE : New Hydrogen Data Have Been Reported by Researchers at GlaxoSm..
3h ago GENMAB A/S : GSK and Genmab receive FDA approval for Arzerra® ofatumumab as firs..
4h ago Novartis-GSK asset swap offers template for pharma and beyond
5h ago GLAXOSMITHKLINE : GSK receives US approval for once-weekly type 2 diabetes treat..
6h ago GLAXOSMITHKLINE : Barnes Foundation Announces $500,000 Endowment Gift from GSK t..
8h ago GLAXOSMITHKLINE : *s&p capital iq cuts glaxosmithkline to 'hold' ('buy') - price..
15h ago GLAXOSMITHKLINE : Gsk swaps oncology for vaccines with novartis
15h ago GLAXOSMITHKLINE : *deutsche bank raises glaxosmithkline price target to 1750 pen..
16h ago ASTRAZENECA : Ukraine tensions could see move to
1d ago Novartis, Valeant bids herald new deal-making era for pharma
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Income Statement Evolution
GlaxoSmithKline plc : Income Statement Evolution
More Financials
Dynamic quotes